Q-omics provides the consensus-scored DPYS profile across patient tissues and cancer cell-line models. DPYS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DPYS is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, DPYS protein abundance shows 18,302 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, LUAD, and PDAC as cancer lineages where DPYS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPYS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPYS survival associations across molecular data types. DPYS RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPYS RNA expression–survival associations across cancer types. High DPYS expression shows unfavorable associations in UVM and STAD, but favorable associations in KIRC, MESO, SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DPYS RNA expression.
This table summarizes DPYS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DPYS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPYS shows lower tumor expression in LUAD, KICH, KIRP, LIHC, LUSC and BRCA. The LUAD box plot shows higher DPYS RNA expression in normal versus tumor tissue (log2 FC = −0.441, t-test p < 0.001).
This table shows molecular features associated with DPYS in patient tissues and cancer cell lines. In patient samples, DPYS shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPYS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
